VBLT News and Press, Vascular Biogenics Ltd. From 09/01/22

VBL Therapeutics ( NASDAQ: VBLT ) said it had received a written notification from the Nasdaq Stock Market, notifying the company that it is not in compliance with the minimum bid price requirement. The company said the closing bid price of the VBL’s ordinary shares...

TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification...

VBL Therapeutics press release ( NASDAQ: VBLT ): Q2 GAAP EPS of -$0.12. At June 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $34.5 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and rest...

TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate upd...

Israeli biotech Vascular Biogenics ( NASDAQ: VBLT ) announced an approximately 35% cut to its workforce on Tuesday as part of an initiative to reduce operating expenses and preserve capital. In conjunction with the cost cutting measures, directors, Dr. Ron Cohen, Dr. Benne...

TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preser...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s undoubtedly a disappointing day for Vascular Biogenics (NASDAQ: VBLT ), also known as VBL Therapeutics, and for VBLT stock holders. A fresh press release disclosed the company’s results for a prop...

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...

Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...

Vascular Biogenics ( NASDAQ: VBLT ) was downgraded to Neutral from Buy at H.C. Wainwright after the company's ovarian cancer drug ofra-vec failed a phase 3 trial. Vascular stock fell post-market July 19 following the news. As of premarket July 20, VBLT shares have shed -...